Pacific Biosciences Of California (NASDAQ: PACB)
Pacific Biosciences Of California Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Pacific Biosciences Of California Company Info
Pacific Biosciences is a leader in the latest generation of human DNA sequencing.
News & Analysis
Investing in Genetic Sequencing Stocks
Cathie Wood Just Added $5 Million of This Stock After It Had a Steep Pullback. Is It a No-Brainer Buy?
This innovator is targeting a huge, rapidly growing market.
3 Things About Pacific Biosciences of California That Smart Investors Know
Anyone thinking about buying shares should know them, too.
Why Shares of Pacific Biosciences of California Are Under Pressure Today
Preliminary fourth-quarter results reached a record high but didn't quite meet expectations.
These 2 Stocks Could Threaten Tuesday's Market Bounce
Investors are trying to get on an even keel after a rough start to 2022.
3 Genomics Stocks That Could Soar 60% or Better, According to Wall Street
The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it.
This Biotech Just Made History. Will Its Stock Follow?
Twenty years after the human genome was sequenced, a new wave of discovery has begun.
2 Top Biotech Picks to Buy and Hold for the Next 10 Years
Incredible scientific advances could reward investors -- if they have the patience.
Valuation
Earnings Transcripts
Pacific Biosciences of California (PACB) Q2 2022 Earnings Call Transcript
PACB earnings call for the period ending June 30, 2022.
Pacific Biosciences of California (PACB) Q4 2021 Earnings Call Transcript
PACB earnings call for the period ending December 31, 2021.
Pacific Biosciences of California (PACB) Q3 2021 Earnings Call Transcript
PACB earnings call for the period ending September 30, 2021.
Pacific Biosciences of California (PACB) Q2 2021 Earnings Call Transcript
PACB earnings call for the period ending June 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.